


A stylized illustration of a human torso from the waist up, rendered in a glowing orange-red wireframe style. The spine and ribcage are visible. Two kidneys are highlighted in a bright green glow, positioned on either side of the spine in the lower back area.

40 MILLION PEOPLE
LIVE WITH KIDNEY DISEASES.
700,000 INDIVIDUALS
HAVE KIDNEY FAILURE.

THERE IS NO CURE.

KIDNEY X
INNOVATION ACCELERATOR

“Dialysis today doesn’t look much different than it did 60 years ago. More innovation is needed, because patients deserve better.”

— Eric D. Hargan,
Deputy Secretary of the
Department of Health and Human Services



KidneyX is a public-private partnership to



Reward and incentivize breakthrough innovations in kidney care by funding new ideas through a series of competitive prizes



Clear a path to commercialization for disruptive therapies and technologies by providing better coordination among HHS, NIH, FDA, and CMS



Create a sense of urgency to bring breakthrough therapies to patients, including fostering multidisciplinary collaboration and engaging the investment community

Why KidneyX is Needed

- ❌ Medicare annually spends \$35 billion treating kidney failure and \$114 billion managing kidney diseases
- ❌ Kidney failure is still managed with dialysis, a therapy invented 50 years ago, and there are no cures
- ❌ Lack of private investment and venture capital, misaligned government incentives, and a complex regulatory process inhibit innovative ideas from becoming therapies available to patients

Why KidneyX is the Solution

- ✅ Incentivizes the accelerated development and commercialization of disruptive technologies
- ✅ Provides merit-based, non-dilutive funding to promising innovators selected through a competitive process for kidney patients to address unmet patient needs
- ✅ Bridges the gap between research and market-ready products

PUBLIC	PRIVATE
\$25M FY20 congressional appropriation support	\$25M committed by ASN
\$125M congressional funding over 5 years	\$100M in fundraising over 5 years
PARTNERSHIP	
\$250M total driving kidney innovation over 5 years	

KidneyX Focus Areas + Potential Products



REDESIGN DIALYSIS: October 2018 - Q2 2020

Wearable or implantable dialyzers, bio-artificial kidneys, xenotransplant technology, etc.



MEDICATIONS

Drugs specifically designed to treat and slow progression of kidney diseases, as well as encompass the needs of kidney transplant patients



DEVICES

Devices that support the management and treatment of kidney diseases that are not dialyzers (such as vascular access technologies, etc.)



DIAGNOSTICS

Point-of-care or at home testing kits, real time kidney monitoring, etc.



PATIENT-CENTERED TOOLS

Tools designed to identify and track disease, applications to empower patients to manage kidney diseases (e.g., apps)